Clinical trial
Study Evaluating the Effect of Lecozotan SR on the QTc Interval
NCT00499642 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00499642 |
|---|---|
| Title | Study Evaluating the Effect of Lecozotan SR on the QTc Interval |
| Official title | A Single-Dose, Double-Blind, Crossover, Placebo- and Moxifloxacin (Open-Label)-Controlled Study of the Effects of Lecozotan SR on Cardiac Repolarization in Healthy Adult Subjects |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Healthy |
| Intervention type | Drug |
| Interventions | Lecozotan SR, Moxifloxacin |
| Start date | Jun 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jul 11, 2007 |
| Last update posted | Dec 28, 2007 |
| Countries | France |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: